Navigation Links
Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
Date:2/17/2009

    DUSSELDORF, Germany, February 17 /PRNewswire/ --

    - Sales Grow by 10.7% to EUR1.06bn

    - Adjusted Earnings per Share Improves by 36.6% From EUR1.34 Euro to
      EUR1.83

    - Adjusted EBITDA Margin Rises From 19.0 to 19.5%

    - CEO Dr. Axel Herberg: "Following the record year in 2008 Gerresheimer
      again considers itself well equipped to meet the global challenges in
      2009 and is aiming for further substantial sales growth of 6% to 7% in
      the core business."

In 2008 Gerresheimer AG had another record year marked by important milestones, and achieved all its published objectives. The international Group with its main base in Dusseldorf, Germany, increased its sales by 10.7% (12.8% on a like-for-like exchange-rate basis) and thereby passed the billion euro mark. Operating results (Adjusted EBITDA) rose by 13.7% to EUR206.4m (prior year: EUR181.6m). The Adjusted EBITDA margin reached 19.5% in 2008 (prior year: 19%). There was a substantial improvement of 36.6% in adjusted earnings per share in the past financial year to EUR1.83 (prior year EUR1.34).

"Our strategy of internationalization and focus is bearing fruit," says Dr. Axel Herberg, CEO of Gerres-heimer AG. "Even in a phase of worldwide economic downturn, pharmaceutics and life science are still growth markets and, with its broad technology base and worldwide presence, Gerresheimer has a strong position here." The shareholders of Gerresheimer AG should participate in the success of Gerresheimer AG as in the prior year. The Management Board and Supervisory Board of Gerresheimer AG will therefore propose to the Shareholders' Meeting that a dividend of EUR0.40 per share is paid.

In December 2008, Gerresheimer AG was included in the second-largest German selection index MDax. This means increased visibility for our company on capital markets, and greater appeal for our shares.

Further substa
'/>"/>

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
11. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. An ... and biotechnology industries is anticipated. Nanotechnology will ... development - from formulations for optimal delivery ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:9/2/2015)... R.I. , Sept. 2, 2015  Neurotech ... been enrolled in the multicenter Phase 2 clinical ... the long-term treatment of recurrent subfoveal choroidal neovascularization ... NT-503 is a unique vascular endothelial growth factor ... ECT implant. "This landmark proof-of-concept study ...
(Date:9/2/2015)... ZIONA, Israel , September 2, ... TASE: BVXV) today announced the intent of the National Institute ... National Institutes of Health (NIH) within the Department of Health ... trial to be held in the United States ... the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Functional Analysis in Yeast ,,, Regulation of ... Tanya Hosfield ,Stratagene , Stratagene ... express,and functionally analyze eukaryotic genes in the budding ... one of four different yeast,selective markers in the ...
... Cycler allows rapid,amplification of rare mRNA , , Donald D. ... University of Illinois at Chicago , , , ... Figure 1: RoboCycler 40 Temperature Cycler In Situ, ... situ adapter system for the RoboCycler 40, ...
... thermoshaker , Jeff Braman ,Stratagene , , ... , , ... round-bottom plate were used to cultivate bacterial clones ... phase rates of bacterial growth, were equivalent ...
Cached Biology Technology:Epitope-Tagging Vectors for Functional Analysis in Yeast 2Epitope-Tagging Vectors for Functional Analysis in Yeast 3Epitope-Tagging Vectors for Functional Analysis in Yeast 4Epitope-Tagging Vectors for Functional Analysis in Yeast 5Epitope-Tagging Vectors for Functional Analysis in Yeast 6Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,Tissue 2Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,Tissue 3Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,Tissue 4Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,Tissue 5Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,Tissue 6High-Throughput Cultivation of Bacterial Clones 2High-Throughput Cultivation of Bacterial Clones 3
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ... Arabia Biomedical Sensors Market - Growth, Trends & Forecasts ... The Saudi Arabia Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... mentioned as pack animals in the biblical stories of Abraham, ... not domesticated in the Land of Israel until centuries after ... challenging the Bible,s historicity, this anachronism is direct proof that ... Now Dr. Erez Ben-Yosef and Dr. Lidar Sapir-Hen of ...
... TORONTO, February 3, 2014 Women with schizophrenia are ... and other serious pregnancy and delivery complications as women ... the Institute for Clinical Evaluative Sciences (ICES) and Women,s ... today in the British Journal of Obstetrics and ...
... 2014) Those two crooked beady eyes peeking out of a ... food in the murky waters of the Chesapeake Bay. They ... of a crab from an adolescent into a full-fledged adult. ... Maryland recently discovered a new hormone in those eyestalks responsible ...
Cached Biology News:Finding Israel's first camels 2Finding Israel's first camels 3Women with schizophrenia at higher risk of pregnancy and delivery complications: Study 2Hormone in crab eyes makes it possible for females to mate and care for their young 2
C1-inhibitor (C1-INH)...
Procollagen type I C-terminal propeptide (human, PICP)...
... provides a comprehensive microarray service for ... embedded within non-coding RNAs (ncRNAs) using ... probe design, which enables highly sensitive ... RNAs (1). This comprehensive service includes ...
... LC micro-fractionation, spotting and preparation for ... LC eluent can be accurately and ... trace amounts. This allows for automatic ... measurements. When used in conjunction with ...
Biology Products: